Nidanilimab (CAN04) is a fully humanized monoclonal antibody targeting IL1RAP, characterized by a high affinity with a dissociation constant (Kd) of 1.10 pM. This antibody effectively inhibits signaling pathways mediated by IL1?? and IL1??, thereby enhancing immune system responses against tumor cells. Nidanilimab is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), offering significant potential for elucidating disease mechanisms and therapeutic interventions in these cancers.
Nidanilimab (CAN04) is a fully humanized monoclonal antibody targeting IL1RAP, characterized by a high affinity with a dissociation constant (Kd) of 1.10 pM. This antibody effectively inhibits signaling pathways mediated by IL1?? and IL1??, thereby enhancing immune system responses against tumor cells. Nidanilimab is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), offering significant potential for elucidating disease mechanisms and therapeutic interventions in these cancers.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
